| Literature DB >> 24477285 |
Wan-Yu Lin1, Bo-Wei Chen2, Chiung-Yao Huang3, Zhi-Hong Wen4, Ping-Jyun Sung5, Jui-Hsin Su6, Chang-Feng Dai7, Jyh-Horng Sheu8.
Abstract
New cembranoids, sarcocrassocolides P-R (1-3) and four known compounds (4-7) were isolated from the soft coral Sarcophyton crassocaule. The structures of the metabolites were determined by extensive spectroscopic analysis. Compounds 3-5 and 7 were shown to exhibit cytotoxicity toward a limited panel of cancer cell lines and all compounds 1-7 displayed potent in vitro anti-inflammatory activity in lipopolysaccharide (LPS)-stimulated RAW264.7 macrophage cells by inhibiting the expression of inducible nitric oxide synthase (iNOS) protein. Compound 7 also showed significant activity in reducing the accumulation of cyclooxygenase-2 (COX-2) protein in the same macrophage cells.Entities:
Mesh:
Substances:
Year: 2014 PMID: 24477285 PMCID: PMC3944518 DOI: 10.3390/md12020840
Source DB: PubMed Journal: Mar Drugs ISSN: 1660-3397 Impact factor: 5.118
Chart 1Structures of new metabolites 1–3, and known compounds 4–7.
NMR spectroscopicdata for Sarcrocrassocolides M–O(1–3).
| Sarcrocrassocolide P (1) | Sarcrocrassocolide Q (2) | Sarcrocrassocolide R (3) | ||||
|---|---|---|---|---|---|---|
| position | δC, mult. a | δH ( | δC, mult. a | δH ( | δC, mult. c | δH ( |
| 1 | 38.5, CH | 3.11, brd (9.5) c | 37.7, CH | 3.06, brs | 40.5, CH | 3.02, d (11.0) |
| 2 | 37.3, CH2 | 1.80, m | 35.7, CH2 | 2.05, t (5.0) | 39.3, CH2 | 2.14, m |
| 1.32, ddd (14.5, 10.5, 9.5) | 1.80, m | 1.82, ddd (19.0, 5.5, 1.5) | ||||
| 3 | 73.1, CH | 3.73, t (10.0) | 75.8, CH | 5.04, dd (6.5, 5.0) | 71.6, CH | 4.25, d (5.0) |
| 4 | 89.9, C | 74.7, C | 150.5, C | |||
| 5 | 36.4, CH2 | 1.94, t (11.5) | 37.9, CH2 | 1.68, m | 31.2, CH2 | 2.16, m |
| 1.81, m | 2.12, m | |||||
| 6 | 23.1, CH2 | 2.26, m | 23.1, CH2 | 2.18, m | 23.4, CH2 | 2.59, m |
| 2.15, m | 2.21, m | |||||
| 7 | 125.7, CH | 5.08, t (7.0) | 123.3, CH | 5.13, t (7.0) | 126.3, CH | 5.07, d (10.5) |
| 8 | 135.8, C | 136.5, C | 133.9, C | |||
| 9 | 39.4, CH2 | 2.28, m | 37.6, CH2 | 2.21, m | 36.7, CH2 | 2.29, d (13.0) |
| 2.09, m | 2.09, m | |||||
| 10 | 24.7, CH2 | 2.44, qd (10.0, 2.5) | 24.6, CH2 | 2.34, m | 24.4, CH2 | 2.17, m |
| 2.11, m | 2.24, m | 1.31, m | ||||
| 11 | 127.3, CH | 5.32, dd (10.0, 3.5) | 129.3, CH | 5.32, brt (7.0) | 61.7, CH | 2.56, dd (11.0, 4.0) |
| 12 | 130.3, C | 129.2, C | 59.7, C | |||
| 13 | 77.5, CH | 5.40, s | 76.5, CH | 5.37, s | 46.5, CH2 | 2.00, dd (14.0, 11.5) |
| 1.24, d (14.0) | ||||||
| 14 | 79.1, CH | 5.28, brs | 82.7, CH | 4.43, dd (5.0, 2.0) | 81.1, CH | 4.32, d (11.5) |
| 15 | 140.5, C | 140.5, C | 139.5, C | |||
| 16 | 170.1, C | 169.8, C | 170.1, C | |||
| 17 | 120.9, CH2 | 6.24, d (2.0) | 122.2, CH2 | 6.23, d (2.5) | 123.2, CH2 | 6.29, d (1.5) |
| 5.65, d (2.0) | 5.78, d (2.5) | 5.69, d (1.5) | ||||
| 18 | 19.7, CH3 | 1.44, s | 24.4, CH3 | 1.44, s | 107.3, CH2 | 5.17, s |
| 4.78, s | ||||||
| 19 | 16.0, CH3 | 1.67, s | 16.8, CH3 | 1.65, s | 14.9, CH3 | 1.76, s |
| 20 | 14.5, CH3 | 1.72, s | 14.6, CH3 | 1.72, s | 17.5, CH3 | 1.38, s |
| 4-OAc | 22.1, CH3 | 2.04, s | ||||
| 172.1, C | ||||||
| 3-OAc | 21.2, CH3 | 2.08, s | ||||
| 170.4, C | ||||||
| 13-OAc | 20.8, CH3 | 1.99, s | 20.8, CH3 | 2.03, s | ||
| 169.3, C | 169.5, C | |||||
a Spectra recorded at 125 MHz in CDCl3; b Spectra recorded at 500 MHz in CDCl3; c Spectra recorded at 100 MHz in CDCl3; d Spectra recorded at 400 MHz in CDCl3.
Figure 1COSY and HMBC correlations for 1 and 3.
Figure 2Key NOESY correlations for 1–3.
Cytotoxicity (ED50 µM) of compounds 1–3.
| Compound | DLD-1 a | CCRF-CEM b | HL-60 c |
|---|---|---|---|
|
| 21.8 | 48.8 | 24.9 |
|
| 35.8 | 73.1 | 18.6 |
|
| 10.0 | 28.1 | 8.7 |
|
| 5.7 | 6.3 | (–) d |
|
| 3.8 | 8.7 | 7.3 |
|
| 27.7 | 41.9 | 34.6 |
|
| 7.9 | 11.1 | 8.4 |
| Doxorubicin | 0.77 | 1.16 | 0.046 |
a DLD-1: human colon adenocarcinoma; b CCRF-CEM: human T-cell acute lymphoblastic leukaemia; c HL-60: human promyelocytic leukemia; d (–): ED50 > 50 µM.
Figure 3Effect of compounds 1–7 on the expression of inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2) proteins in RAW264.7 macrophage cells by immunoblot analysis. (A) Immunoblots of iNOS and β-actin; (B) Immunoblots of COX-2 and β-actin. The values are mean ± SEM. (n = 6). Relative intensity of the lipopolysaccharide (LPS) alone stimulated group was taken as 100%; * Significantly different from LPS alone stimulated group (* p < 0.05); a stimulated with LPS; b stimulated with LPS in the presence of 1–7 (10 µM).